Yield Spectrum Expands, Investors Face Choices
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 17 2026
0mins
Source: Yahoo Finance
- Yield Comparison: Johnson & Johnson (JNJ) offers a 2.26% yield with a $1.34 quarterly dividend, marking its 64th consecutive annual increase, which underscores its robust cash flow and shareholder return capability, thereby boosting investor confidence.
- Financial Services Performance: Morgan Stanley (MS) provides a 2.1% yield backed by a 27.1% ROTCE for Q1 2026 and $1.75 billion in buybacks, indicating strong performance in capital management and shareholder returns.
- Risk vs. Reward: The Iran war has heightened inflation expectations, forcing investors to choose between 3% municipal bonds and 13% business development companies, reflecting market sensitivity to risk and the pursuit of yield, which impacts investment strategies.
- Yield Structure: The current yield spectrum ranges from 3% to 13%, requiring investors to weigh safety against high-risk returns, especially amid ongoing Middle East conflicts, as the demand for yield remains strong in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAH
Wall Street analysts forecast CAH stock price to fall
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 234.750
Low
209.00
Averages
225.18
High
244.00
Current: 234.750
Low
209.00
Averages
225.18
High
244.00
About CAH
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and others. It also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as owns a urology management services organization (MSO). Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. It connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Choppy Markets as Healthcare Stocks Surge Amid AI Retreat
- Market Volatility: U.S. stocks experienced choppy trading on Friday, with the S&P 500 on track for a nearly 2% drop this week, indicating a soft overall market performance in June that investors should closely monitor for sentiment shifts.
- Oil Price Decline: U.S. benchmark WTI crude is expected to close under $70 per barrel, remaining under pressure despite President Trump's comments on Iran's drone attacks, reflecting a fragile supply-demand dynamic in the oil market.
- Healthcare Sector Surge: The healthcare sector rose over 7% this week, outperforming the S&P 500, with Cardinal Health, Johnson & Johnson, and Eli Lilly poised for record closes on Friday, indicating a renewed investor interest in healthcare amid a retreat from AI stocks.
- Honeywell Spin-off Plan: Honeywell is set to split into two standalone companies, with shareholders receiving one share of Honeywell Aerospace for every two shares owned, and analysts have initiated coverage with a buy rating, anticipating strong growth for the Aerospace division.
See More
Cardinal Health Stock Trim Analysis
- Stock Trim: Cardinal Health (CAH) sold 50 shares, reducing its holdings to 375 shares and decreasing its portfolio weighting from 2.50% to 2.25%, reflecting a cautious approach to market fluctuations.
- Sector Performance: The healthcare sector has been the best-performing this week, with Cardinal Health, Johnson & Johnson, and Eli Lilly benefiting from this trend, indicating a strong rebound in the overall market.
- Price Recovery: Cardinal Health's stock has rallied 6% this week and 20% this month, reaching an all-time high on Thursday, marking a significant recovery since the Iran war, with investors optimistic about its future prospects.
- Target Price Increase: Following the trim, Cardinal Health's price target was raised from $225 to $245, aligning with market consensus, demonstrating confidence in the company's growth potential.
See More
Micron's Strong Earnings Boost Chip Stocks
- Strong Earnings: Micron reported quarterly revenue of $6 billion, exceeding market expectations and causing its stock to surge 10% in after-hours trading, reflecting robust performance in the memory market.
- Optimistic Guidance: The company provided a positive outlook for the upcoming quarter, projecting a 15% revenue growth, indicating strong confidence in market demand, which may attract more investor interest.
- Industry Ripple Effect: Micron's impressive results not only boosted its own stock but also lifted other memory and chip-related companies, creating a positive ripple effect across the industry and enhancing overall market confidence in the semiconductor sector.
- Inflation Data Watch: With the Fed set to release its favored inflation gauge, market expectations regarding future monetary policy will further influence tech stock performance, prompting investors to closely monitor related developments.
See More
Stocks Rebound as Falling Oil Prices Boost Market Sentiment
- Market Rebound: Stocks climbed on Wednesday as the S&P 500 and Nasdaq Composite rebounded from two consecutive days of declines, primarily driven by falling oil prices, with West Texas Intermediate crude dropping below $70 a barrel for the first time since March, indicating improved market sentiment.
- Impact of Energy Prices: The decline in energy prices led to lower Treasury yields, benefiting interest rate-sensitive sectors such as housing and home improvement, with Home Depot shares advancing over 5%, reflecting increased investor confidence in these sectors.
- Nike CFO Transition: Nike announced that David Denton, a former executive at Lowe's and Pfizer, will succeed Matthew Friend as CFO effective August 17, and although shares fell nearly 2% on Wednesday, analysts believe this change will have limited impact on future performance, with the upcoming earnings report being closely watched for potential guidance adjustments.
- Alphabet Replaces Verizon: Alphabet will replace Verizon in the Dow Jones Industrial Average starting Monday, and while the stock rose 1.7% on the announcement, analyst Jeff cautioned against viewing this index addition as a major catalyst, emphasizing that it is largely symbolic and recognizes Alphabet's significance in the broader economy.
See More
Amgen vs Iovance: Investment Comparison
- Amgen's Stability: In FY 2025, Amgen reported nearly $36.7 billion in revenue, a 9.9% increase year-over-year, with a net income of approximately $7.7 billion and a net margin of about 21%, showcasing its strong profitability and stability in the global market.
- Iovance's Rapid Growth: Iovance achieved approximately $263.5 million in revenue for FY 2025, marking a 60.6% increase, yet it reported a net loss of nearly $391 million, indicating its innovative potential in cancer treatment but highlighting its lack of profitability.
- Risk Comparison: Amgen faces risks from government pricing regulations and competition from biosimilars, while Iovance must navigate the complexities of manufacturing personalized therapies and uncertainties regarding market adoption, which could impact their future market performance.
- Valuation Differences: Amgen has a forward P/E ratio of 15.1, reflecting its value as a mature company, whereas Iovance, still unprofitable, has a P/S ratio of 5.4, indicating its high-risk investment profile in the early growth stage.
See More
Tango Therapeutics Appoints New Board Member
- New Board Appointment: Tango Therapeutics has appointed Robert Azelby to its Board of Directors, bringing over 30 years of executive management, commercial product launches, and corporate governance experience, which is expected to provide strategic guidance and industry insights to the company.
- Extensive Industry Background: Azelby currently serves on the boards of ADC Therapeutics, Autolus Therapeutics, and Cardinal Health, Inc., and previously held the position of President and CEO at Eliem Therapeutics, enhancing his influence in the biotechnology sector.
- R&D Progress: Tango is advancing its investigational PRMT5 inhibitor, Vopimetostat, through late-stage development aimed at treating pancreatic cancer patients, demonstrating the company's potential and commitment in the cancer treatment space.
- Stock Price Movement: TNGX closed at $28.50 on Monday, up 1.89%, while pre-market trading shows a slight decline of 0.04% to $28.49, reflecting market interest in the company's new appointment.
See More
Choppy Markets as Healthcare Stocks Surge Amid AI Retreat
- Market Volatility: U.S. stocks experienced choppy trading on Friday, with the S&P 500 on track for a nearly 2% drop this week, indicating a soft overall market performance in June that investors should closely monitor for sentiment shifts.
- Oil Price Decline: U.S. benchmark WTI crude is expected to close under $70 per barrel, remaining under pressure despite President Trump's comments on Iran's drone attacks, reflecting a fragile supply-demand dynamic in the oil market.
- Healthcare Sector Surge: The healthcare sector rose over 7% this week, outperforming the S&P 500, with Cardinal Health, Johnson & Johnson, and Eli Lilly poised for record closes on Friday, indicating a renewed investor interest in healthcare amid a retreat from AI stocks.
- Honeywell Spin-off Plan: Honeywell is set to split into two standalone companies, with shareholders receiving one share of Honeywell Aerospace for every two shares owned, and analysts have initiated coverage with a buy rating, anticipating strong growth for the Aerospace division.
See More
Cardinal Health Stock Trim Analysis
- Stock Trim: Cardinal Health (CAH) sold 50 shares, reducing its holdings to 375 shares and decreasing its portfolio weighting from 2.50% to 2.25%, reflecting a cautious approach to market fluctuations.
- Sector Performance: The healthcare sector has been the best-performing this week, with Cardinal Health, Johnson & Johnson, and Eli Lilly benefiting from this trend, indicating a strong rebound in the overall market.
- Price Recovery: Cardinal Health's stock has rallied 6% this week and 20% this month, reaching an all-time high on Thursday, marking a significant recovery since the Iran war, with investors optimistic about its future prospects.
- Target Price Increase: Following the trim, Cardinal Health's price target was raised from $225 to $245, aligning with market consensus, demonstrating confidence in the company's growth potential.
See More
Micron's Strong Earnings Boost Chip Stocks
- Strong Earnings: Micron reported quarterly revenue of $6 billion, exceeding market expectations and causing its stock to surge 10% in after-hours trading, reflecting robust performance in the memory market.
- Optimistic Guidance: The company provided a positive outlook for the upcoming quarter, projecting a 15% revenue growth, indicating strong confidence in market demand, which may attract more investor interest.
- Industry Ripple Effect: Micron's impressive results not only boosted its own stock but also lifted other memory and chip-related companies, creating a positive ripple effect across the industry and enhancing overall market confidence in the semiconductor sector.
- Inflation Data Watch: With the Fed set to release its favored inflation gauge, market expectations regarding future monetary policy will further influence tech stock performance, prompting investors to closely monitor related developments.
See More
Stocks Rebound as Falling Oil Prices Boost Market Sentiment
- Market Rebound: Stocks climbed on Wednesday as the S&P 500 and Nasdaq Composite rebounded from two consecutive days of declines, primarily driven by falling oil prices, with West Texas Intermediate crude dropping below $70 a barrel for the first time since March, indicating improved market sentiment.
- Impact of Energy Prices: The decline in energy prices led to lower Treasury yields, benefiting interest rate-sensitive sectors such as housing and home improvement, with Home Depot shares advancing over 5%, reflecting increased investor confidence in these sectors.
- Nike CFO Transition: Nike announced that David Denton, a former executive at Lowe's and Pfizer, will succeed Matthew Friend as CFO effective August 17, and although shares fell nearly 2% on Wednesday, analysts believe this change will have limited impact on future performance, with the upcoming earnings report being closely watched for potential guidance adjustments.
- Alphabet Replaces Verizon: Alphabet will replace Verizon in the Dow Jones Industrial Average starting Monday, and while the stock rose 1.7% on the announcement, analyst Jeff cautioned against viewing this index addition as a major catalyst, emphasizing that it is largely symbolic and recognizes Alphabet's significance in the broader economy.
See More
Amgen vs Iovance: Investment Comparison
- Amgen's Stability: In FY 2025, Amgen reported nearly $36.7 billion in revenue, a 9.9% increase year-over-year, with a net income of approximately $7.7 billion and a net margin of about 21%, showcasing its strong profitability and stability in the global market.
- Iovance's Rapid Growth: Iovance achieved approximately $263.5 million in revenue for FY 2025, marking a 60.6% increase, yet it reported a net loss of nearly $391 million, indicating its innovative potential in cancer treatment but highlighting its lack of profitability.
- Risk Comparison: Amgen faces risks from government pricing regulations and competition from biosimilars, while Iovance must navigate the complexities of manufacturing personalized therapies and uncertainties regarding market adoption, which could impact their future market performance.
- Valuation Differences: Amgen has a forward P/E ratio of 15.1, reflecting its value as a mature company, whereas Iovance, still unprofitable, has a P/S ratio of 5.4, indicating its high-risk investment profile in the early growth stage.
See More
Tango Therapeutics Appoints New Board Member
- New Board Appointment: Tango Therapeutics has appointed Robert Azelby to its Board of Directors, bringing over 30 years of executive management, commercial product launches, and corporate governance experience, which is expected to provide strategic guidance and industry insights to the company.
- Extensive Industry Background: Azelby currently serves on the boards of ADC Therapeutics, Autolus Therapeutics, and Cardinal Health, Inc., and previously held the position of President and CEO at Eliem Therapeutics, enhancing his influence in the biotechnology sector.
- R&D Progress: Tango is advancing its investigational PRMT5 inhibitor, Vopimetostat, through late-stage development aimed at treating pancreatic cancer patients, demonstrating the company's potential and commitment in the cancer treatment space.
- Stock Price Movement: TNGX closed at $28.50 on Monday, up 1.89%, while pre-market trading shows a slight decline of 0.04% to $28.49, reflecting market interest in the company's new appointment.
See More
